Polymeric nanocarriers for drug delivery in osteosarcoma treatment

Current Pharmaceutical Design

Volumn 21, Issue 36, 2015, Pages 5187-5197

  Gu, Xueyuan ^a,b   Ding, Jianxun ^a   Zhang, Zhiyu ^b   Li, Qin ^b   Zhuang, Xiuli ^a   Chen, Xuesi ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Active targeting; Controlled drug delivery; Osteosarcoma therapy; Passive targeting; Polymeric nanocarriers

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ANTINEOPLASTIC AGENT; GLYCOSIDASE; NANOCARRIER; PHOSPHOLIPASE; PHOTOSENSITIZING AGENT; PROTEINASE; TOXIC SUBSTANCE; DRUG CARRIER; NANOPARTICLE; POLYMER;

CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; HUMAN; NONHUMAN; OSTEOSARCOMA; PH; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; ADOLESCENT; ANIMAL; BONE NEOPLASMS; CHEMISTRY; CHILD; DRUG DESIGN;

ADOLESCENT; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NANOPARTICLES; OSTEOSARCOMA; POLYMERS;

EID: 84947940651     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150923095618     Document Type: Review

References (90)

1. Bacci G, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 2008; 98: 415-20.
2. Ta H, Dass C, Choong P, Dunstan D. Osteosarcoma treatment: State of the art. Cancer Metastasis Rev 2009; 28: 247-63.
3. Machak GN, Tkachev SI, Solovyev YN, et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc 2003; 78: 147-55.
4. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-5.
5. Carrle D, Bielack S. Osteosarcoma lung metastases detection and principles of multimodal therapy. In: Jaffe N, Bruland OS, Bielack SS, Eds. Pediatric and adolescent osteosarcoma. Dordrecht: Springer 2009; pp. 165-84.
6. Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 2010; 11: 670-8.
7. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - Where do we stand? A state of the art review. Cancer Treat Rev 2014; 40: 523-32.
8. Ding J, He C, Xiao C, Chen J, Zhuang X, Chen X. pH-responsive drug delivery systems based on clickable poly(L-glutamic acid)- grafted comb copolymers. Macromol Res 2012; 20: 292-301.
9. Ding J, Chen L, Xiao C, Chen L, Zhuang X, Chen X. Noncovalent interaction-assisted polymeric micelles for controlled drug delivery. Chem Commun 2014; 50: 11274-90.
10. Ding J, Xiao C, He C, et al. Facile preparation of a cationic poly(amino acid) vesicle for potential drug and gene co-delivery. Nanotechnology 2011; 22: 494012.
11. Ding J, Xiao C, Zhuang X, He C, Chen X. Direct formation of cationic polypeptide vesicle as potential carrier for drug and gene. Mater Lett 2012; 73: 17-20.
12. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm 2010; 385: 113-42.
13. Ding J, Shi F, Xiao C, et al. One-step preparation of reductionresponsive poly(ethylene glycol)-poly(amino acid)s nanogels as efficient intracellular drug delivery platforms. Polym Chem 2011; 2: 2857-64.
14. Ding J, Zhuang X, Xiao C, et al. Preparation of photo-cross-linked pH-responsive polypeptide nanogels as potential carriers for controlled drug delivery. J Mater Chem 2011; 21: 11383-91.
15. Zhang Y, Xiao C, Li M, et al. Co-delivery of 10- hydroxycamptothecin with doxorubicin conjugated prodrugs for enhanced anticancer efficacy. Macromol Biosci 2013; 13: 584-94.
16. Zhang Y, Xiao C, Li M, et al. Core-cross-linked micellar nanoparticles from a linear-dendritic prodrug for dual-responsive drug delivery. Polym Chem 2014; 5: 2801-8.
17. Huang F, You M, Chen T, Zhu G, Liang H, Tan W. Self-assembled hybrid nanoparticles for targeted co-delivery of two drugs into cancer cells. Chem Commun 2014; 50: 3103-5.
18. Zhong Y, Wang C, Cheng R, et al. cRGD-directed, NIR-responsive and robust AuNR/PEG-PCL hybrid nanoparticles for targeted chemotherapy of glioblastoma in vivo. J Control Release 2014; 195: 63-71.
19. Daglar B, Ozgur E, Corman ME, Uzun L, Demirel GB. Polymeric nanocarriers for expected nanomedicine: current challenges and future prospects. RSC Adv 2014; 4: 48639-59.
20. Bae YH. Drug targeting and tumor heterogeneity. J Control Release 2009; 133: 2-3.
21. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
22. Kamaly N, Xiao ZY, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem Soc Rev 2012; 41: 2971-3010.
23. Ernsting MJ, Murakami M, Roy A, Li SD. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release 2013; 172: 782-94.
24. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
25. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev 2011; 63: 623-39.
26. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000; 11: S81-91.
27. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: Relevance to drug delivery. Cell Mol Life Sci 2009; 66: 2873-96.
28. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986; 46: 638-92.
29. Gratton SEA, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 2008; 105: 11613-8.
30. Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub- 100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011; 6: 815-23.
31. Chen J, Ding J, Xiao C, Zhuang X, Chen X. Emerging antitumor applications of extracellularly reengineered polymeric nanocarriers. Biomater Sci 2015; 3: 988-1001.
32. Goncalves M, Maciel D, Capelo D, et al. Dendrimer-assisted formation of fluorescent nanogels for drug delivery and intracellular imaging. Biomacromolecules 2014; 15: 492-9.
33. Zhang F, Zhang S, Pollack SF, et al. Improving paclitaxel delivery: In vitro and in vivo characterization of PEGylated polyphosphoester- based nanocarriers. J Am Chem Soc 2015; 137: 2056-66.
34. Ding J, Li C, Zhang Y, Xu W, Wang J, Chen X. Chirality-mediated polypeptide micelles for regulated drug delivery. Acta Biomater 2015; 11: 346-55.
35. Li C, Xu W, Ding J, et al. Micellization of antineoplastic agent to significantly upregulate efficacy and security. Macromol Biosci 2015; 15: 328-41.
36. Wang B, Yu X-C, Xu S-F, Xu M. Paclitaxel and etoposide coloaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma. J Nanobiotechnol 2015; 13: 22.
37. Tan ML, Friedhuber AM, Dass CR. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model. J Pharm Pharmacol 2013; 65: 35-43.
38. Friedhuber AM, Chandolu V, Manchun S, Donkor O, Sriamornsak P, Dass CR. Nucleotropic doxorubicin nanoparticles decrease cancer cell viability, destroy mitochondria, induce autophagy and enhance tumour necrosis. J Pharm Pharmacol 2015; 67: 68-77.
39. Dolmans D, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3: 380-7.
40. Toyokuni S. Novel aspects of oxidative stress-associated carcinogenesis. Antioxid Redox Signal 2006; 8: 1373-7.
41. Burch S, London C, Seguin B, Rodriguez C, Wilson BC, Bisland SK. Treatment of canine osseous tumors with photodynamic therapy: a pilot study. Clin Orthop Rel Res 2009; 467: 1028-34.
42. Duchi S, Sotgiu G, Lucarelli E, et al. Mesenchymal stem cells as delivery vehicle of porphyrin loaded nanoparticles: Effective photoinduced in vitro killing of osteosarcoma. J Control Release 2013; 168: 225-37.
43. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004; 5: 497-508.
44. He WJ, Hosseinkhani H, Mohammadinejad R, et al. Polymeric nanoparticles for therapy and imaging. Polym Adv Technol 2014; 25: 1216-25.
45. Bisland SK, Burch S. Photodynamic therapy of diseased bone. Photodiagnosis Photodyn Ther 2006; 3: 147-55.
46. Ghahremani FH, Sazgarnia A, Bahreyni-Toosi MH, Rajabi O, Aledavood A. Efficacy of microwave hyperthermia and chemotherapy in the presence of gold nanoparticles: an in vitro study on osteosarcoma. Int J Hyperthermia 2011; 27: 625-36.
47. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anticancer drug delivery. J Control Release 2010; 148: 135-46.
48. Cheng R, Meng FH, Deng C, Klok HA, Zhong ZY. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 2013; 34: 3647-57.
49. Liu J, Huang Y, Kumar A, et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv 2014; 32: 693- 710.
50. Ding J, Xu W, Zhang Y, et al. Self-reinforced endocytoses of smart polypeptide nanogels for "on-demand" drug delivery. J Control Release 2013; 172: 444-55.
51. Sun D, Ding J, Xiao C, Chen J, Zhuang X, Chen X. Preclinical evaluation of antitumor activity of acid-sensitive PEGylated doxorubicin. ACS Appl Mater Interfaces 2014; 6: 21202-14.
52. Chen J, Ding J, Zhang Y, Xiao C, Zhuang X, Chen X. Polyion complex micelles with gradient pH-sensitivity for adjustable intracellular drug delivery. Polym Chem 2015; 6: 397-405.
53. Xu W, Ding J, Xiao C, Li L, Zhuang X, Chen X. Versatile preparation of intracellular-acidity-sensitive oxime-linked polysaccharidedoxorubicin conjugate for malignancy therapeutic. Biomaterials 2015; 54: 72-86.
54. Feron O. Pyruvate into lactate and back: From the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 2009; 92: 329-33.
55. Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Control Release 2008; 132: 164-70.
56. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013; 12: 991-1003.
57. Chitkara D, Kumar N. BSA-PLGA-based core-shell nanoparticles as carrier system for water-soluble drugs. Pharm Res 2013; 30: 2396-409.
58. Goncalves M, Figueira P, Maciel D, et al. pH-sensitive Laponite((R))/doxorubicin/alginate nanohybrids with improved anticancer efficacy. Acta Biomater 2014; 10: 300-7.
59. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001; 30: 1191-212.
60. Ding J, Chen J, Li D, et al. Biocompatible reduction-responsive polypeptide micelles as nanocarriers for enhanced chemotherapy efficacy in vitro. J Mat Chem B 2013; 1: 69-81.
61. Aluri S, Janib SM, Mackay JA. Environmentally responsive peptides as anticancer drug carriers. Adv Drug Deliv Rev 2009; 61: 940-52.
62. Saito G, Swanson JA, Lee KD. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003; 55: 199-215.
63. Maciel D, Figueira P, Xiao S, et al. Redox-responsive alginate nanogels with enhanced anticancer cytotoxicity. Biomacromolecules 2013; 14: 3140-6.
64. Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev 2012; 64: 866-84.
65. Thorpe PE, Wallace PM, Knowles PP, et al. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res 1987; 47: 5924- 31.
66. Chou A, Gorlick R. Chemotherapy resistance in osteosarcoma: Current challenges and future directions. Expert Rev Anticancer Ther 2006; 6: 1075-85.
67. Susa M, Iyer AK, Ryu K, et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer 2009; 9: 399.
68. Sen DK, Sarin GS. Biological variations of lysozyme concentration in the tear fluids of healthy-persons. Br J Ophthalmol 1986; 70: 246-8.
69. Cole AM, Thapa DR, Gabayan V, Liao HI, Liu L, Ganz T. Decreased clearance of pseudomonas aeruginosa from airways of mice deficient in lysozyme M. J Leukoc Biol 2005; 78: 1081-5.
70. Chin A, Suarato G, Meng Y. Evaluation of physicochemical characteristics of hydrophobically modified glycol chitosan nanoparticles and their biocompatibility in murine osteosarcoma and osteoblast- like cells. J Nanotechnol Smart Mater 2014; 1: 1-7.
71. Peer D, Karp JM, Hong S, FaroKhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2: 751-60.
72. Cheng ZL, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: Cost versus benefit of adding targeting and imaging capabilities. Science 2012; 338: 903-10.
73. Saha RN, Vasanthakumar S, Bende G, Snehalatha M. Nanoparticulate drug delivery systems for cancer chemotherapy. Mol Membr Biol 2010; 27: 215-31.
74. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release 2012; 161: 175-87.
75. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J Control Release 2012; 164: 265-75.
76. van Kempen L, van den Oord JJ, van Muijen GNP, Weidle UH, Bloemers HPJ, Swart GWM. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 2000; 156: 769-74.
77. Nelissen J, Torensma R, Pluyter M, et al. Molecular analysis of the hematopoiesis supporting osteoblastic cell line U2-OS. Exp Hematol 2000; 28: 422-32.
78. Kristiansen G, Pilarsky C, Wissmann C, et al. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003; 54: 34-43.
79. Federman N, Chan J, Nagy JO, et al. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma 2012; 2012: 126906.
80. Barat B, Sirk SJ, McCabe KE, et al. Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection. Bioconjug Chem 2009; 20: 1474-81.
81. Liu Y, Sun J, Lian H, Cao W, Wang Y, He Z. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxelloaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. J Pharm Sci 2014; 103: 1538-47.
82. Saul JM, Annapragada AV, Bellamkonda RV. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 2006; 114: 277-87.
83. Hassan SE, Bekarev M, Kim MY, et al. Cell surface receptor expression patterns in osteosarcoma. Cancer 2012; 118: 740-9.
84. Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther 2013; 137: 89-99.
85. Posthumadeboer J, Piersma SR, Pham TV, et al. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer 2013; 109: 2142-54.
86. Gu W, Wu C, Chen J, Xiao Y. Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration. Int J Nanomed 2013; 8: 2305-17.
87. Costantino L, Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today 2012; 17: 367-78.
88. Melancon MP, Stafford RJ, Li C. Challenges to effective cancer nanotheranostics. J Control Release 2012; 164: 177-82.
89. Cabral H, Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. J Control Release 2014; 190: 465-76.
90. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009; 100: 572-9.